These two peptides are shopped for together and cannot be bought the same way. Sermorelin runs a typical $189 a month across 146 sellers that publish a figure, and ipamorelin has no lawful compounded route in the United States at all. That difference is not a matter of which is more popular or better studied. It comes down to two separate places in federal law, and they say opposite things.
| Sermorelin | Ipamorelin | |
|---|---|---|
| Sellers publishing a monthly price | 146 | 0 |
| Lowest published month | $90 | No published market |
| Typical (median) month | $189 | No published market |
| Highest published month | $356 | No published market |
| Sellers naming it in their own listings | See the price board | 23 |
| Named on a federal compounding list | 503B Category 1, as an approved drug's component | 503B Category 2, significant safety risks |
Why sermorelin can be compounded
Federal law lets a pharmacy compound from a bulk substance in three cases, and one of them is a substance that is a component of a drug the agency has approved[1].
Sermorelin qualifies through GEREF, which was approved as an injection under two applications and discontinued by its holder in 2008. FDA determined on March 4, 2013 that GEREF had not been withdrawn from sale for reasons of safety or effectiveness, which is the finding that keeps the component route open[2].
The outsourcing-facility list says the same thing in its own notation. “Sermorelin Acetate” sits in 503B Category 1 carrying the double asterisk that list uses to designate bulk drug substances that are components of FDA-approved drugs[3].
What that permits, and what it does not, is set out in is sermorelin FDA approved.
Why ipamorelin cannot
Ipamorelin is on the other list, by name. “Ipamorelin Acetate” appears in 503B Category 2, the group FDA describes as bulk drug substances that raise significant safety risks[3].
FDA gives its reason on the page that accompanies that category. Compounded drugs containing ipamorelin acetate may pose a risk of immunogenicity for certain routes of administration, because of the potential for aggregation or peptide-related impurities[4].
The agency adds two more points. Ipamorelin acetate contains unnatural amino acids, which add to the complexity of characterizing it, and a study published in the literature identified serious adverse events including death when ipamorelin was given intravenously to improve gastric motility[4].
For the other injected routes, FDA says it has not identified safety-related information and therefore lacks enough information to know whether the drug would cause harm[4].
The 503A list is the pharmacy-side door, and ipamorelin is absent from all three of its categories in the May 14, 2026 update[5]. Neither door is open.
What has actually been measured in people
Ipamorelin has been through a controlled trial in patients, which is more than most peptides sold this way can claim. It did not work.
A phase 2, multicenter, double-blind, placebo-controlled study enrolled 117 adults having small or large bowel resection, of whom 114 made up the safety and modified intent-to-treat populations[6].
Participants received intravenous infusions of 0.03 mg/kg ipamorelin or placebo twice daily, from the first postoperative day for up to seven days or until discharge[6].
Median time to the first tolerated solid meal was 25.3 hours with ipamorelin against 32.6 hours with placebo, a difference the authors reported at p = 0.15[6]. Their conclusion was that there were no significant differences on the key or secondary efficacy analyses[6].
A 2026 review of peptides marketed direct to patients places ipamorelin in the group it calls unapproved, alongside CJC-1295, BPC-157 and TB-500, and notes that rigorous human safety data for that group are scarce[7]. It lists sermorelin among the approved peptides[7].
What this means for a quote in front of you
A menu that prices sermorelin and ipamorelin side by side is pricing one product that a pharmacy may lawfully make and one that it may not. The two figures are not alternatives to each other, whatever the layout suggests.
If the sermorelin prescription is the one being considered, the visit and the steps around it are covered in sermorelin prescription, and the form comparison is in sermorelin tablets.
The broader question of which peptides have a lawful route at all, and what the labels “research use only” and “compounded” each mean on a checkout page, is covered in RUO peptides and are peptides legal.